Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | TSHR | P16473 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21399728 | 0.88 | CYP3A4 (0.64) | ATMCYP3A4ALDH1A1TSHRMAPT | |
| SCHEMBL2851560 | 0.85 | ATM (0.60) | ATMCYP3A4ALDH1A1TSHRMAPT | |
| SCHEMBL4444864 | 0.85 | ATM (0.60) | ATMCYP3A4ALDH1A1TSHRMAPT | |
| SCHEMBL2851564 | 0.85 | ATM (0.60) | ATMCYP3A4ALDH1A1TSHRMAPT | |
| Hydrochloric Acid SCHEMBL2853610 | 0.84 | ATM (0.59) | ATMCYP3A4ALDH1A1TSHRMAPT | |
| Hydrochloric Acid SCHEMBL2853606 | 0.84 | ATM (0.59) | ATMCYP3A4ALDH1A1TSHRMAPT | |
| SCHEMBL21469067 | 0.83 | ATM (0.68) | ATMCYP3A4ALDH1A1TSHRCTSK | |
| SCHEMBL8530402 | 0.83 | ATM (0.68) | ATMCYP3A4ALDH1A1TSHRCTSK | |
| SCHEMBL30460502 | 0.83 | ATM (0.68) | ATMCYP3A4ALDH1A1TSHRCTSK | |
| SCHEMBL6558237 | 0.83 | ATM (0.57) | ATMCYP3A4ALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663979-B1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-7238714-B2 | Aryl or heteroaryl amide compounds | PFIZER JAPAN, INC. (JP) | 2007-07-03 | — | — | US | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | SYK 3551/4885ATM 4784/4885CYP3A4 221/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | SYK 1021/4885ATM 4110/4885CYP3A4 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.